West Nile Virus

U.S. NIH awards $15.5 million for West Nile virus, dengue vaccines

Published in TB and Outbreaks Week, January 4th, 2005

Hawaii Biotech has been awarded $15.5 million through three separate grants from the U.S. National Institutes of Health (NIH).

The grants will fund preclinical development of the company's West Nile virus and dengue vaccines and a significant portion of the Phase I human clinical trial for the dengue vaccine. These grants bring total federal funding for Hawaii Biotech's Emerging Disease/Bioterrorism program to over $31 million, including $12 million in Department of Defense and NIH anthrax funding as well as smaller federally funded projects in ebola, malaria and tick-borne encephalitis. The company also has a self-funded flu program.

"Our goal is to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2005-01-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry